1. Treatment with β-elemene combined with paclitaxel inhibits growth, migration, and invasion and induces apoptosis of ovarian cancer cells by activation of STAT-NF-κB pathway
   Fu Xiaomeng et al, 2020, Brazilian Journal of Medical and Biological Research CrossRef
2. Octreotide and Octreotide-derived delivery systems
   Mingliang Fan et al, 2023, Journal of Drug Targeting CrossRef
3. Selective Delivery of Clinically Approved Tubulin Binding Agents through Covalent Conjugation to an Active Targeting Moiety
   Samuel E. Collyer et al, 2022, Current Medicinal Chemistry CrossRef
4. The development of peptide-drug conjugates (PDCs) strategies for paclitaxel
   Longkun Wang et al, 2022, Expert Opinion on Drug Delivery CrossRef
5. Identification and imaging of miR-155 in the early screening of lung cancer by targeted delivery of octreotide-conjugated chitosan-molecular beacon nanoparticles
   Hai-Zhen Zhu et al, 2018, Drug Delivery CrossRef
6. A Compressive Review about Taxol®: History and Future Challenges
   Julia Gallego-Jara et al, 2020, Molecules CrossRef
7. Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer
   Chenxi Wang et al, 2023, Expert Opinion on Therapeutic Targets CrossRef
8. Octreotide modified liposomes that co-deliver paclitaxel and neferine effectively inhibit ovarian cancer metastasis by specifically binding to the SSTR2 receptors
   Yang Liu et al, 2024, Journal of Drug Delivery Science and Technology CrossRef